BLUE - Bluebird bio's Lentiglobin nabs PRIME status in Europe

Bluebird bio's (BLUE) LentiGlobin, an investigational gene therapy (bb1111) for the treatment of sickle cell disease ((SCD)) was granted eligibility to the Priority Medicines ((PRIME)) program by the EMA.PRIME, akin to Breakthrough Therapy status in the U.S., provides for more intensive guidance on development and accelerated review of the market application. SCD is a progressive and debilitating genetic disease caused by a mutation in the ?-globin gene that leads to the production of abnormal sickle hemoglobin (HbS), resulting in chronic hemolytic anemia and vasculopathy.Wall Street Analysts rating is Bullish.

For further details see:

Bluebird bio’s Lentiglobin nabs PRIME status in Europe